Michele Donato is an Oncology physician affiliated with Hackensack University Medical Center. OpenAlex indexes 221 publications with 6,074 citations (h-index 35); ClinicalTrials.gov lists 6 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
92 2nd St
Hackensack, NJ 076012191
Telephone
551-996-8297Provider last certified this registry record 26 Jan 2022.
Clinical trials
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
Sponsor: Hackensack Meridian Health
- Expanded Access to Convalescent Plasma for Treatment of COVID-19
Sponsor: Hackensack Meridian Health
- Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection
Sponsor: Hackensack Meridian Health
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20256 payments
- Daiichi Sankyo Inc.Program year20252 payments
- Astellas Pharma US IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
46.2%Hematopoietic Stem Cell Mobilizer34.3%Plerixafor100%Part D + Part B≥17 patientsSelective immunosuppressants6.1%Rezurock100%Part D≥16 patients+ 3 more classes in this area
Anti-infectives
26.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor7.5%Valacyclovir100%Part D≥47 patientsShort-acting sulfonamides7.5%Sulfamethoxazole-Trimethoprim100%Part D≥36 patients+ 5 more classes in this area
Metabolism & gastrointestinal
9.8%Corticosteroid3.5%Prednisone100%Part D≥24 patientsH2 blocker1.6%Famotidine100%Part D≥13 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Parrillo, MD
Hackensack University Medical Center
Andre Goy, MD
Hackensack University Medical Center
David Vesole, MD
Hackensack University Medical Center
Caron Rockman, MD
Hackensack University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”